Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck’s cancer drug Erbitux to be made available to more NHS patients

Merck’s cancer drug Erbitux to be made available to more NHS patients

6th March 2017

Merck's metastatic colorectal cancer drug Erbitux (cetuximab) is to be made available to more patients in the UK on the NHS following a new recommendation from the National Institute of Health and Care Excellence (NICE).

NICE has issued a positive Final Appraisal Determination for the drug, which grants it approval for wider use on the NHS in combination with FOLFIRI and FOLFOX. When taken together, these drugs can work as an effective first-line treatment for patients with RAS wild-type metastatic colorectal cancer.

Colorectal cancer has one of the lowest rates of survival of all types of the disease and there are currently few effective treatments for patients diagnosed with the illness. As a result, NICE's recommendation for Merck's Erbitux has the potential to improve quality of life for a significant number of patients.

Jola Gore-Booth, founder and chief executive of colorectal cancer patient advocacy group EuropaColon, commented: "Patients with metastatic colorectal cancer in the UK have very limited access to effective first-line treatments. We are therefore delighted with NICE's decision."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

Image: decade3d via iStockADNFCR-8000103-ID-801833210-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.